Cargando…
Toxin-Specific Antibodies for the Treatment of Clostridium difficile: Current Status and Future Perspectives (†)
Therapeutic agents targeting bacterial virulence factors are gaining interest as non-antibiotic alternatives for the treatment of infectious diseases. Clostridium difficile is a Gram-positive pathogen that produces two primary virulence factors, enterotoxins A and B (TcdA and TcdB), which are respon...
Autores principales: | Hussack, Greg, Tanha, Jamshid |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
MDPI
2010
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3153223/ https://www.ncbi.nlm.nih.gov/pubmed/22069622 http://dx.doi.org/10.3390/toxins2050998 |
Ejemplares similares
-
An update on antibody-based immunotherapies for Clostridium difficile infection
por: Hussack, Greg, et al.
Publicado: (2016) -
Application of Assisted Design of Antibody and Protein Therapeutics (ADAPT) improves efficacy of a Clostridium difficile toxin A single-domain antibody
por: Sulea, Traian, et al.
Publicado: (2018) -
Neutralization of Clostridium difficile toxin B with V(H)H-Fc fusions targeting the delivery and CROPs domains
por: Hussack, Greg, et al.
Publicado: (2018) -
Targeting surface-layer proteins with single-domain antibodies: a potential therapeutic approach against Clostridium difficile-associated disease
por: Kandalaft, Hiba, et al.
Publicado: (2015) -
Structure-guided design of a potent Clostridioides difficile toxin A inhibitor
por: Hussack, Greg, et al.
Publicado: (2023)